Lumenis gets antitrust case and questions from SEC (US Securities and Exchange Commission)
This article was originally published in Clinica
Executive Summary
Laser company Lumenis has had an antitrust and patent infringement claim slapped on it just days after receiving a request from the US Securities and Exchange Commission (SEC) for documents and information. Shares in the company fell by over 30% to around $9, although the company also had some good news in the form of an agreement to refinance a $100 million term loan and $71 million in convertible bonds.